Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)2022-07-072022-07-072019-03-15O'Bryant, S. E., Ferman, T. J., Zhang, F., Hall, J., Pedraza, O., Wszolek, Z. K., Como, T., Julovich, D., Mattevada, S., Johnson, L. A., Edwards, M., Hall, J., & Graff-Radford, N. R. (2019). A proteomic signature for dementia with Lewy bodies. Alzheimer's & dementia (Amsterdam, Netherlands),11, 270-276. https://doi.org/10.1016/j.dadm.2019.01.0062352-8729https://hdl.handle.net/20.500.12503/31537Introduction: We sought to determine if a proteomic profile approach developed to detect Alzheimer's disease would distinguish patients with Lewy body disease from normal controls, and if it would distinguish dementia with Lewy bodies (DLB) from Parkinson's disease (PD). Methods: Stored plasma samples were obtained from 145 patients (DLB n = 57, PD without dementia n = 32, normal controls n = 56) enrolled from patients seen in the Behavioral Neurology or Movement Disorders clinics at the Mayo Clinic, Florida. Proteomic assays were conducted and analyzed as per our previously published protocols. Results: In the first step, the proteomic profile distinguished the DLB-PD group from controls with a diagnostic accuracy of 0.97, sensitivity of 0.91, and specificity of 0.86. In the second step, the proteomic profile distinguished the DLB from PD groups with a diagnostic accuracy of 0.92, sensitivity of 0.94, and specificity of 0.88. Discussion: These data provide evidence of the potential utility of a multitiered blood-based proteomic screening method for detecting DLB and distinguishing DLB from PD.http://creativecommons.org/licenses/by-nc-nd/4.0/biomarker screeningblood biomarkersdementia with Lewy bodiesdetectiondiagnostic accuracyParkinson's diseaseParkinson DiseaseProteomicsLewy Body DiseaseArticleCopyright © 2019 The Authors11